Real-world outcomes with addition of bevacizumab to first-line chemotherapy for epithelial ovarian cancer

In clinical trials, adding bevacizumab to first-line (IL) chemotherapy for stage III/IV epithelial ovarian cancer (EOC) significantly improved progression-free survival but not overall survival. The retrospective, nationwide BEV1L database study investigated the real-world value of adding bevacizumab to 1L chemotherapy for stage III/IV EOC. Among patients with high-risk prognostic factors, median time to next treatment was 13.6 months with 1L chemotherapy plus bevacizumab versus 11.7 months with chemotherapy alone (HR 0.85; p=0.03) with a trend towards longer median OS (31.1 months versus 27.4 months (HR 0.84; p=0.052). For patients without high-risk prognostic factors, real-world outcomes did not differ with the addition of bevacizumab. The authors conclude that these real-world results suggest that clinical benefit of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk prognostic factors.